Navigating the Diagnostic Gray Zone in Preimplantation Genetic Testing
A critical review in Human Reproduction examines the persistent challenges in Preimplantation Genetic Testing for Aneuploidy (PGT-A), a key tool in molecular diagnostics for embryo selection. While next-generation sequencing (NGS) and haplotype-based methods have advanced the detection of whole-chromosome abnormalities, significant variability in laboratory thresholds and reporting practices leads to inconsistent classifications of the same embryo. This analytical uncertainty is most pronounced for complex findings like chromosomal mosaicism and segmental abnormalities, which show poor predictive value for clinical outcomes compared to clear meiotic aneuploidies. The article underscores a widening gap between high-resolution genetic data and actionable clinical decision-making, highlighting an urgent need for validation frameworks that integrate analytical precision with robust clinical evidence.
Study Significance: For pathologists and molecular diagnosticians, this analysis stresses the critical importance of laboratory quality control and standardized reporting in genetic testing. The variability in PGT-A interpretation directly impacts diagnostic accuracy and patient outcomes, emphasizing that technological complexity alone does not guarantee clinical utility. This calls for a concerted effort within the field to develop consensus guidelines that align molecular findings with validated biomarkers and real-world clinical data to improve the reliability of embryo biopsy analysis.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
